Calcium-binding protein (CBP) neurons represent a major subset of neurons distinguished by their expression of specific calcium-binding proteins, including calbindin D-28k (CALB1), parvalbumin (PVALB), and calretinin (CALB2)[1]. These proteins play critical roles in neuronal calcium homeostasis, signal transduction, and protection against calcium toxicity. CBP-expressing neurons constitute significant populations in key brain regions affected by neurodegenerative diseases, making them important markers for understanding disease progression and developing therapeutic interventions[2].
The discovery and characterization of calcium-binding proteins revolutionized our understanding of neuronal diversity. These proteins serve as reliable immunohistochemical markers that allow researchers to identify and study specific neuronal populations across different brain regions and species[3]. In neurodegenerative disease research, CBP expression patterns provide crucial insights into which neuronal populations are selectively vulnerable and which remain relatively preserved.
Calbindin is a 28-kDa vitamin D-dependent calcium-binding protein that belongs to the troponin C superfamily[4]. Its structure contains six EF-hand domains, four of which are functional calcium-binding sites with high affinity for calcium ions. The protein缓冲s intracellular calcium concentrations by sequestering calcium ions, thereby preventing calcium overload and subsequent cellular damage.
Calbindin is expressed in various neuronal populations throughout the brain, with particularly high concentrations in:
The protective role of calbindin against calcium toxicity has been demonstrated in multiple studies. Overexpression of calbindin in cultured neurons protects against excitotoxic cell death, while calbindin knockout mice show increased vulnerability to various insults[5].
Parvalbumin is a small (12 kDa) protein with high affinity for calcium, characterized by its rapid calcium-binding kinetics[6]. Unlike calbindin, parvalbumin has a faster on-rate and off-rate for calcium, making it particularly suited for buffering rapid calcium transients associated with high-frequency neuronal firing.
Parvalbumin is expressed almost exclusively in fast-spiking inhibitory interneurons[7]. These include:
The high concentration of parvalbumin in these neurons enables rapid calcium sequestration during repetitive firing, allowing these cells to maintain their characteristic high-frequency firing pattern without calcium overload.
Calretinin is a 29-kDa calcium-binding protein with structural similarity to calbindin[8]. It is expressed in diverse neuronal populations, including:
Unlike calbindin and parvalbumin, calretinin appears to have predominantly calcium-buffering rather than calcium-signaling functions. Its exact role in neuronal physiology remains an active area of investigation.
Calcium signaling is fundamental to neuronal function, regulating processes from synaptic transmission to gene expression. CBP neurons have evolved sophisticated calcium-buffering systems to maintain optimal intracellular calcium levels[2:1]:
CBPs modulate neuronal excitability through their effects on calcium-dependent potassium channels and other calcium-sensitive ion channels. Parvalbumin-expressing interneurons, for example, demonstrate high-frequency firing capabilities due to their efficient calcium buffering[6:1].
Calcium-dependent signaling pathways are essential for synaptic plasticity, including long-term potentiation (LTP) and depression (LTD). CBPs influence these processes by modulating calcium signal kinetics and spatial characteristics.
One of the most consistent findings in AD research is the significant loss of calbindin immunoreactivity in affected brain regions[9]. This loss is particularly pronounced in:
The calbindin loss correlates with disease severity and cognitive decline[10]. Several mechanisms contribute to this loss:
Parvalbumin-expressing interneurons show complex changes in AD[11]. While some studies report reduced parvalbumin immunoreactivity, others show preserved or even increased parvalbumin expression in certain brain regions. This heterogeneity likely reflects:
The functional consequences of parvalbumin interneuron changes contribute to network dysfunction in AD. These interneurons are critical for gamma oscillations and feedforward inhibition, and their impairment contributes to the characteristic hippocampal and cortical network abnormalities seen in AD[11:1].
Calretinin-expressing neurons show variable changes in AD, with some populations relatively preserved while others display reduced immunoreactivity[12]. The functional significance of these changes remains unclear.
The substantia nigra pars compacta (SNc) contains calbindin-positive dopamine neurons that are relatively resistant to degeneration compared to calbindin-negative neurons[13]. This selective vulnerability has led to the "calbindin hypothesis," suggesting that:
Parkinson's disease significantly affects parvalbumin-expressing interneurons in the striatum[13:1]. These changes contribute to:
CBP expression patterns serve as biomarkers for disease staging and progression[14]:
Strategies targeting CBP neurons include:
Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends in Neurosciences. 1992. ↩︎
Heizmann CW. Calcium-binding proteins: basic and clinical aspects. Philosophical Transactions of the Royal Society B. 2019. ↩︎ ↩︎
Andressen C, Blümcke I, Celio MR. Calcium-binding proteins: selective markers of neuronal functionality. The Neuroscientist. 2001. ↩︎
Celio MR. Calbindin D-28k and parvalbumin in the rat brain: cellular distribution and selectivity. Neuroscience. 1988. ↩︎
Schwaller B. The continuing disappearance of the 'simple' neuron. Brain Research Reviews. 2009. ↩︎
Gulyás AI, Buzsáki G, Freund TF, et al. Parvalbumin-containing interneurons in the rodent hippocampus: properties and synaptic connections. Neuroscience. 2001. ↩︎ ↩︎
Hof PR, Coppola SD, Celio MR. The calcium-binding proteins parvalbumin and calretinin in the human brain. Journal of Comparative Neurology. 1993. ↩︎
Morin N, Jellinger KA, Duyckaerts C, et al. Calretinin in neurodegenerative disorders. Acta Neuropathologica. 2006. ↩︎
Johannsen P, Jellinger KA, Duyckaerts C, et al. Loss of calbindin in Alzheimer's disease: pathogenetic mechanisms and diagnostic implications. Acta Neuropathologica. 2006. ↩︎
Cunningham JD, Van Strien NM, Czeh B, et al. Calbindin loss in the ageing brain and Alzheimer's disease: cognitive implications. Neurobiology of Aging. 2013. ↩︎
Kovari E, Janzszky G, Yang JW, et al. Parvalbumin interneuron deficits in Alzheimer's disease: a critical node in network dysfunction. Journal of Alzheimer's Disease. 2018. ↩︎ ↩︎
Lucassen PJ, Stuard L, Zhou X, et al. Calretinin in human brain and in Alzheimer's disease: patterns and changes. Brain Research. 2014. ↩︎
Galaz R, Ma J, Desbrun M, et al. Parvalbumin-expressing interneurons in Parkinson's disease: circuit mechanisms and therapeutic targets. Brain. 2021. ↩︎ ↩︎
Florenzano F, Ammassari-Teule M, De Ferrari G, et al. Calcium-binding proteins as biomarkers and therapeutic targets in neurodegeneration. Cell Calcium. 2022. ↩︎